TNFRSF9 and neoplasm: Overall, our data shows that treatment with the bispecific OX40/CD137 dual-agonist FS120m induces functional reprogramming of murine Tregs, resulting in their production of effector cytokines and loss of their suppressive function, thus promoting tumor regression through both direct and indirect mechanisms.